181 related articles for article (PubMed ID: 22773825)
1. Fertility drugs and young-onset breast cancer: results from the Two Sister Study.
Fei C; Deroo LA; Sandler DP; Weinberg CR
J Natl Cancer Inst; 2012 Jul; 104(13):1021-7. PubMed ID: 22773825
[TBL] [Abstract][Full Text] [Related]
2. Thyroid cancer risk in women with infertility and association with fertility medications in Taiwan.
Ding DC; Chen W; Wang JH; Lin SZ; Sung FC
Cancer; 2019 May; 125(10):1701-1708. PubMed ID: 30645760
[TBL] [Abstract][Full Text] [Related]
3. Long-term relationship of ovulation-stimulating drugs to breast cancer risk.
Brinton LA; Scoccia B; Moghissi KS; Westhoff CL; Niwa S; Ruggieri D; Trabert B; Lamb EJ
Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):584-93. PubMed ID: 24700523
[TBL] [Abstract][Full Text] [Related]
4. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study.
Kurta ML; Moysich KB; Weissfeld JL; Youk AO; Bunker CH; Edwards RP; Modugno F; Ness RB; Diergaarde B
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1282-92. PubMed ID: 22707710
[TBL] [Abstract][Full Text] [Related]
5. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs.
Guleria S; Kjær SK; Albieri V; Frederiksen K; Jensen A
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1986-1992. PubMed ID: 31533944
[TBL] [Abstract][Full Text] [Related]
6. Fertility drugs and the risk of breast cancer.
Ricci E; Parazzini F; Negri E; Marsico S; La Vecchia C
Hum Reprod; 1999 Jun; 14(6):1653-5. PubMed ID: 10357995
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer risk after use of fertility drugs: stimulating new controversy.
Brinton LA
J Natl Cancer Inst; 2012 Jul; 104(13):962-4. PubMed ID: 22773824
[No Abstract] [Full Text] [Related]
8. Clomiphene Stair-Step Protocol for Women With Polycystic Ovary Syndrome.
Jones T; Ho JR; Gualtieri M; Bruno-Gaston J; Chung K; Paulson RJ; Bendikson KA
Obstet Gynecol; 2018 Jan; 131(1):91-95. PubMed ID: 29215516
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risk after exposure to fertility drugs.
Lo Russo G; Spinelli GP; Tomao S; Rossi B; Frati L; Panici PB; Vici P; Codacci Pisanelli G; Tomao F
Expert Rev Anticancer Ther; 2013 Feb; 13(2):149-57. PubMed ID: 23406556
[TBL] [Abstract][Full Text] [Related]
10. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.
Olshan AF; Smith J; Cook MN; Grufferman S; Pollock BH; Stram DO; Seeger RC; Look AT; Cohn SL; Castleberry RP; Bondy ML
Am J Epidemiol; 1999 Nov; 150(9):930-8. PubMed ID: 10547138
[TBL] [Abstract][Full Text] [Related]
11. Fertility Drugs Associated with Thyroid Cancer Risk: A Systematic Review and Meta-Analysis.
Yu Q; Lv X; Liu K; Ma D; Wu Y; Dai W; Jiang H
Biomed Res Int; 2018; 2018():7191704. PubMed ID: 29862285
[TBL] [Abstract][Full Text] [Related]
12. Timing of familial breast cancer in sisters.
Rebora P; Czene K; Reilly M
J Natl Cancer Inst; 2008 May; 100(10):721-7. PubMed ID: 18477799
[TBL] [Abstract][Full Text] [Related]
13. Perinatal and postnatal exposures and risk of young-onset breast cancer.
Diaz-Santana MV; O'Brien KM; D'Aloisio AA; Regalado G; Sandler DP; Weinberg CR
Breast Cancer Res; 2020 Aug; 22(1):88. PubMed ID: 32791983
[TBL] [Abstract][Full Text] [Related]
14. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome.
Brown J; Farquhar C
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD002249. PubMed ID: 27976369
[TBL] [Abstract][Full Text] [Related]
15. WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.
Hughes E; Collins J; Vandekerckhove P
Cochrane Database Syst Rev; 1996 Apr; (1):CD000087. PubMed ID: 17636586
[TBL] [Abstract][Full Text] [Related]
16. Use of fertility drugs and risk of endometrial cancer in an Italian case-control study.
Parazzini F; Pelucchi C; Talamini R; Montella M; La Vecchia C
Eur J Cancer Prev; 2010 Nov; 19(6):428-30. PubMed ID: 20634699
[TBL] [Abstract][Full Text] [Related]
17. Follicle stimulating hormone versus clomiphene citrate in intrauterine insemination for unexplained subfertility: a randomized controlled trial.
Danhof NA; van Wely M; Repping S; Koks C; Verhoeve HR; de Bruin JP; Verberg MFG; van Hooff MHA; Cohlen BJ; van Heteren CF; Fleischer K; Gianotten J; van Disseldorp J; Visser J; Broekmans FJM; Mol BWJ; van der Veen F; Mochtar MH;
Hum Reprod; 2018 Oct; 33(10):1866-1874. PubMed ID: 30137325
[TBL] [Abstract][Full Text] [Related]
18. Is clomiphene citrate stair-step protocol a good alternative to gonadotrophins in clomiphene-resistant PCO patients? Prospective study.
Salaheldin AbdelHamid AM; Rateb AM; Ismail Madkour WA
J Obstet Gynaecol Res; 2016 May; 42(5):547-53. PubMed ID: 26786750
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
[TBL] [Abstract][Full Text] [Related]
20. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
